Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Co-Diagnostics, Inc. Common Stock

Healthcare US CODX

3.23USD
0.11(3.53%)

Last update at 2026-06-23T20:00:00Z

Day Range

2.973.51
LowHigh

52 Week Range

1.3546.50
LowHigh

Fundamentals

  • Previous Close 3.12
  • Market Cap5.91M
  • Volume338574
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-30.17654M
  • Revenue TTM0.62M
  • Revenue Per Share TTM0.47
  • Gross Profit TTM 0.40M
  • Diluted EPS TTM-35.25

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -48.51191M -37.58164M -38.11056M -18.84723M 45.64M
Minority interest - - - - -
Net income -46.89594M -37.63901M -35.33286M -14.23825M 36.66M
Selling general administrative 9.06M 16.16M 14.28M 14.26M 11.55M
Selling and marketing expenses 2.38M 4.48M 6.86M 7.34M 13.40M
Gross profit -0.91098M 2.92M 2.63M 28.74M 86.31M
Reconciled depreciation 1.11M 1.38M 1.22M 1.28M 0.34M
Ebit -31.28335M -40.08131M -42.70623M -11.59129M 46.06M
Ebitda -30.17654M -38.70404M -41.47576M -2.68155M 46.44M
Depreciation and amortization 1.11M 1.38M 1.23M 8.91M 0.38M
Non operating income net other - - - 8.13M -0.42916M
Operating income -31.48764M -40.08131M -42.70623M -11.59129M 46.06M
Other operating expenses 31.91M 44.00M 49.52M 45.81M 51.82M
Interest expense - - - 14.88M 0.47M
Tax provision -1.61598M 0.06M -9.75064M -4.60898M 8.98M
Interest income 0.29M 1.09M 1.05M 0.70M 0.05M
Net interest income 0.29M 1.09M 1.05M 0.70M 0.05M
Extraordinary items - - - - -
Non recurring - - - 15.39M -
Other items - - - - -
Income tax expense -1.61598M 0.06M -2.77769M -4.60898M 8.98M
Total revenue 0.42M 3.92M 6.81M 34.22M 97.89M
Total operating expenses 30.58M 43.00M 45.33M 40.33M 40.25M
Cost of revenue 1.33M 1.00M 4.18M 5.48M 11.57M
Total other income expense net -17.02428M 2.50M 4.60M -7.25594M -0.42916M
Discontinued operations - - - - -
Net income from continuing ops -46.89594M -37.63901M -42.56189M -14.23825M 36.66M
Net income applicable to common shares - - - -14.23825M 36.66M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 24.74M 64.00M 103.65M 123.09M 160.03M
Intangible assets 7.22M 26.10M 26.40M 26.77M 27.20M
Earning assets - - - - -
Other current assets 0.63M 1.34M 1.60M 0.76M 2.34M
Total liab 4.11M 9.69M 17.63M 8.57M 25.56M
Total stockholder equity 20.63M 54.31M 86.01M 114.52M 134.48M
Deferred long term liab - - - 2.42M 7.23M
Other current liab 0.98M 3.11M 3.06M 2.62M 5.77M
Common stock 0.07M 0.04M 0.04M 0.03M 0.03M
Capital stock 0.07M 0.04M 0.04M 0.03M 0.03M
Retained earnings -80.37354M -33.04084M 4.60M 39.93M 54.17M
Other liab - - - 4.64M 12.96M
Good will - - - 0.00000M 14.71M
Other assets - - 0.00000M - 0.07M
Cash 11.88M 2.94M 14.92M 22.97M 88.61M
Cash and equivalents - - - - -
Total current liabilities 3.54M 7.32M 5.75M 3.87M 12.60M
Current deferred revenue 0.01M 0.04M 0.36M - 0.15M
Net debt -10.64805M -0.78436M -11.92631M -22.62589M -88.60723M
Short term debt 0.66M 0.92M 0.84M 0.30M 6.07M
Short long term debt - - - - -
Short long term debt total 1.24M 2.15M 2.99M 0.35M -
Other stockholder equity 100.93M 86.90M 81.23M 74.26M 80.27M
Property plant equipment - - - 2.54M 1.93M
Total current assets 13.69M 32.29M 62.14M 92.73M 115.12M
Long term investments 0.35M 0.73M 0.77M 0.67M 0.07M
Net tangible assets - - - 87.75M 92.57M
Short term investments 0.00000M 26.81M 43.63M 58.29M 1.26M
Net receivables 0.19M 0.13M 0.33M 5.40M 20.91M
Long term debt - - - - -
Inventory 0.99M 1.07M 1.66M 5.31M 2.00M
Accounts payable 1.88M 3.29M 1.48M 0.95M 0.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.42M 0.15M 0.29M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 39.93M 54.17M
Treasury stock - - - -14.21187M -
Accumulated amortization - - - - -
Non currrent assets other 0.35M 0.00000M -0.00000M 0.67M 0.07M
Deferred long term asset charges - - - - -
Non current assets total 11.05M 31.71M 41.51M 30.35M 44.91M
Capital lease obligations 1.24M 2.15M 2.99M 0.35M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 27.08M 17.07M -47.53329M -56.74066M 3.57M
Change to liabilities - - - -4.68507M -0.45524M
Total cashflows from investing activities 26.27M 17.07M 15.39M -58.16817M 4.10M
Net borrowings - - - - -
Total cash from financing activities 11.81M 0.10M -1.36393M -14.03400M 0.45M
Change to operating activities - - - -0.22409M -2.04909M
Net income -46.89594M -37.63901M -35.33286M -14.23825M 36.66M
Change in cash 8.95M -11.98033M -8.05692M -65.63343M 45.63M
Begin period cash flow 2.94M 14.92M 22.97M 88.61M 42.98M
End period cash flow 11.88M 2.94M 14.92M 22.97M 88.61M
Total cash from operating activities -29.13693M -29.15505M -22.08187M 6.57M 41.08M
Issuance of capital stock 11.80M 0.10M 0.00000M - 0.00000M
Depreciation 1.11M 1.38M 1.23M 1.28M 0.34M
Other cashflows from investing activities -0.10257M -0.14375M - - 1.69M
Dividends paid - - - - -
Change to inventory 0.13M 0.27M 0.41M -3.52521M 5.71M
Change to account receivables -0.03180M 0.19M 2.54M 14.96M -8.74085M
Sale purchase of stock - 0.00000M -1.36393M -14.21187M 0.45M
Other cashflows from financing activities 6.97M 0.10M 15.39M -0.30291M -24.70982M
Change to netincome - - - 21.02M 6.98M
Capital expenditures 0.70M 0.75M 1.37M 1.43M 0.67M
Change receivables - - - 14.96M -8.74085M
Cash flows other operating - - - -8.24331M -2.20440M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -65.63343M 45.63M
Change in working capital -3.16720M 2.75M 5.64M 6.37M -2.89645M
Stock based compensation 2.25M 5.43M 8.34M 7.54M 5.51M
Other non cash items 17.57M -1.08286M 0.46M 10.42M 0.54M
Free cash flow -29.83697M -29.90340M -23.44717M 5.14M 40.41M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CODX
Co-Diagnostics, Inc. Common Stock		 0.11 3.53% 3.23 - 15.36 9.49 0.29 5.03 0.52
ABT
Abbott Laboratories		 2.70 3.07% 90.53 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 5.31 1.74% 310.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 1.36 1.72% 80.63 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.27 2.86% 45.60 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Co-Diagnostics, Inc. Common Stock

2401 S. Foothill Dr., Salt Lake City, UT, United States, 84109

Key Executives

Name Title Year Born
Mr. Dwight H. Egan Chairman, CEO & Pres 1953
Mr. Brian L. Brown CPA CFO & Company Sec. 1976
Mr. Reed L. Benson Gen. Counsel 1948
Dr. Brent C. Satterfield Ph.D. Co-Founder & Member of Scientific Advisory Board 1977
Mr. Dan Bohrer CPA VP of Fin. & Accounting NA
Dr. Mark Poritz Ph.D. Chief Scientific Officer NA
Mr. Andrew Benson Head of Investor Relations NA
Dr. Mayuranki Almaula Sr. VP of Overseas Operations & Strategic Alliances NA
Mr. Cameron Gundry Head of Commercialization LATAM/EUR NA
Mr. David Nielsen Chief Operating Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions